Strain-Specific Effects of three Different Native Lactobacillus on Anthropometric Indices, Appetite, and Nesfatin-1 in Obese Adults: A Triple-Blind Randomized Clinical Trial
摘要
Obesity is a multifactorial metabolic disorder often accompanied by gut dysbiosis. Probiotics may restore microbial balance and modulate metabolic and appetite-regulating pathways. Therefore, the present study investigated the strain-specific effects of three native Lactobacillus species on anthropometric indices, appetite, and nesfatin-1 concentrations in obese adults. In this triple-blind, randomized, placebo-controlled clinical trial, 100 obese adults (BMI 30–40 kg/m², aged 18–60 years) were allocated into four groups to receive one sachet daily of L. plantarum (2 × 10⁹ CFU), L. fermentum (2 × 10⁹ CFU), L. rhamnosus (2 × 10⁹ CFU), or placebo for 60 days. Anthropometric indices—including BMI, waist circumference (WC), waist-to-height ratio (WHtR), body roundness index (BRI), a body shape index (ABSI), lipid accumulation product (LAP), and visceral adiposity index (VAI)—were evaluated. A validated Likert-scale questionnaire assessed appetite, and serum nesfatin-1 levels were measured using ELISA. Eighty-nine participants completed the trial. After adjustment for age, sex, and baseline values, L. fermentum supplementation significantly reduced WC (P = 0.049) and BRI (P = 0.048) compared with placebo. Within-group analysis revealed that L. plantarum and L. fermentum significantly decreased WC, WHtR, and BRI (P < 0.05). Both strains also produced significant reductions in appetite scores (P = 0.004 and P < 0.001, respectively). No statistically significant changes in serum nesfatin-1 levels were detected among groups. Supplementation with native L. fermentum and L. plantarum for 60 days improved some anthropometric parameters and appetite in obese adults, independent of significant nesfatin-1 modulation. These findings highlight the strain-specific potential of native probiotics as adjunctive strategies for obesity management. However, future well-designed clinical research with a larger sample and/or extended follow-up is suggested to confirm this evidence.
Trial registration: IRCT, IRCT20220608055106N1, Registered 3 July 2022